Human kappa light chain targeted Pseudomonas exotoxin A - identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development

Journal of Immunological Methods

Volumn 371, Issue 1-2, 2011, Pages 122-133

  Kellner, C ^a   Bleeker, W K ^b   Lammerts van Bueren, J J ^b   Staudinger, M ^a   Klausz, K ^a   Derer, S ^a   Glorius, P ^a   Muskulus, A ^a   de Goeij, B E C G ^b   van de Winkel, J G J ^b,c   Parren, P W H I ^b   Valerius, T ^a   Gramatzki, M ^a   Peipp, M ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b GENMAB   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antibody screening; Antibody therapy; Antibody drug conjugate; Immunotoxin; Pseudomonas exotoxin A; ScFv

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; ANTINEOPLASTIC AGENT; CHIMERIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOTOXIN; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY SCREENING; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CONJUGATION; HUMAN; HUMAN CELL; INDIVIDUALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; TARGET CELL;

ADP RIBOSE TRANSFERASES; ANIMALS; BACTERIAL TOXINS; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXOTOXINS; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOTOXINS; MICE; MODELS, MOLECULAR; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; VIRULENCE FACTORS;

PSEUDOMONAS EXOTOXIN;

EID: 79960936401     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2011.06.023     Document Type: Article

References (43)

1. Bang S., Nagata S., Onda M., Kreitman R.J., Pastan I. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin. Cancer Res. 2005, 11:1545.
2. Barth S., Huhn M., Matthey B., Klimka A., Galinski E.A., Engert A. Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions. Appl. Environ. Microbiol. 2000, 66:1572.
3. Bhattacharyya S., Bhattacharya R., Curley S., McNiven M.A., Mukherjee P. Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:14541.
4. Burris H.A., Rugo H.S., Vukelja S.J., Vogel C.L., Borson R.A., Limentani S., Tan-Chiu E., Krop I.E., Michaelson R.A., Girish S., Amler L., Zheng M., Chu Y.W., Klencke B., O'Shaughnessy J.A. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol. 2011, 29:398.
5. Carter P.J. Potent antibody therapeutics by design. Nat. Rev. Immunol. 2006, 6:343.
6. Carter P.J., Senter P.D. Antibody-drug conjugates for cancer therapy. Cancer J. 2008, 14:154.
7. Dechant M., Weisner W., Berger S., Peipp M., Beyer T., Schneider-Merck T., Lammerts van Bueren J.J., Bleeker W.K., Parren P.W., van de Winkel J.G., Valerius T. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res. 2008, 68:4998.
8. Glennie M.J., French R.R., Cragg M.S., Taylor R.P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 2007, 44:3823.
9. Hermans W.J.J., Ten Haft M.R., Overweel A. Method For Affinity Purification 2006, Vol. WO 2006/059904 A1.
10. Hust M., Jostock T., Menzel C., Voedisch B., Mohr A., Brenneis M., Kirsch M.I., Meier D., Dubel S. Single chain Fab (scFab) fragment. BMC Biotechnol. 2007, 7:14.
11. Krebber A., Bornhauser S., Burmester J., Honegger A., Willuda J., Bosshard H.R., Pluckthun A. Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J. Immunol. Methods 1997, 201:35.
12. Kreitman R.J., Stetler-Stevenson M., Margulies I., Noel P., Fitzgerald D.J., Wilson W.H., Pastan I. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J. Clin. Oncol. 2009, 27:2983.
13. Kreitman R.J., Wilson W.H., Bergeron K., Raggio M., Stetler-Stevenson M., FitzGerald D.J., Pastan I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 2001, 345:241.
14. Krop I.E., Beeram M., Modi S., Jones S.F., Holden S.N., Yu W., Girish S., Tibbitts J., Yi J.H., Sliwkowski M.X., Jacobson F., Lutzker S.G., Burris H.A. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 2010, 28:2698.
15. Kuo S.R., Alfano R.W., Frankel A.E., Liu J.S. Antibody internalization after cell surface antigen binding is critical for immunotoxin development. Bioconjug. Chem. 2009, 20(10):1975.
16. Lammerts van Bueren J.J., Bleeker W.K., Bogh H.O., Houtkamp M., Schuurman J., van de Winkel J.G., Parren P.W. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res. 2006, 66:7630.
17. Lewis Phillips G.D., Li G., Dugger D.L., Crocker L.M., Parsons K.L., Mai E., Blattler W.A., Lambert J.M., Chari R.V., Lutz R.J., Wong W.L., Jacobson F.S., Koeppen H., Schwall R.H., Kenkare-Mitra S.R., Spencer S.D., Sliwkowski M.X. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008, 68:9280.
18. Linenberger M.L. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 2005, 19:176.
19. Lonberg N. Human antibodies from transgenic animals. Nat. Biotechnol. 2005, 23:1117.
20. Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms. Curr. Opin. Immunol. 2008, 20:450.
21. Mazor Y., Barnea I., Keydar I., Benhar I. Antibody internalization studied using a novel IgG binding toxin fusion. J. Immunol. Methods 2007, 321:41.
22. Meister S., Schubert U., Neubert K., Herrmann K., Burger R., Gramatzki M., Hahn S., Schreiber S., Wilhelm S., Herrmann M., Jack H.M., Voll R.E. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007, 67:1783.
23. Pastan I., Hassan R., Fitzgerald D.J., Kreitman R.J. Immunotoxin therapy of cancer. Nat. Rev Cancer 2006, 6:559.
24. Peipp M., Kupers H., Saul D., Schlierf B., Greil J., Zunino S.J., Gramatzki M., Fey G.H. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res. 2002, 62:2848.
25. Ruuls S.R., Lammerts van Bueren J.J., van de Winkel J.G., Parren P.W. Novel human antibody therapeutics: the age of the Umabs. Biotechnol. J. 2008, 3:1157.
26. Schirrmann T., Krauss J., Arndt M.A., Rybak S.M., Dubel S. Targeted therapeutic RNases (ImmunoRNases). Expert. Opin. Biol. Ther. 2009, 9:79.
27. Schneider-Merck T., Lammerts van Bueren J.J., Berger S., Rossen K., van Berkel P.H., Derer S., Beyer T., Lohse S., Bleeker W.K., Peipp M., Parren P.W., van de Winkel J.G., Valerius T., Dechant M. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J. Immunol. 2010, 184:512.
28. Schrama D., Reisfeld R.A., Becker J.C. Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov. 2006, 5:147.
29. Schwemmlein M., Peipp M., Barbin K., Saul D., Stockmeyer B., Repp R., Birkmann J., Oduncu F., Emmerich B., Fey G.H. A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells. Br. J. Haematol. 2006, 133:141.
30. Seetharam S., Chaudhary V.K., FitzGerald D., Pastan I. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. J. Biol. Chem. 1991, 266:17376.
31. Sievers E.L., Larson R.A., Stadtmauer E.A., Estey E., Lowenberg B., Dombret H., Karanes C., Theobald M., Bennett J.M., Sherman M.L., Berger M.S., Eten C.B., Loken M.R., van Dongen J.J., Bernstein I.D., Appelbaum F.R. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 2001, 19:3244.
32. Spangler J.B., Neil J.R., Abramovitch S., Yarden Y., White F.M., Lauffenburger D.A., Wittrup K.D. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:13252.
33. Spooner R.A., Smith D.C., Easton A.J., Roberts L.M., Lord J.M. Retrograde transport pathways utilised by viruses and protein toxins. Virol. J. 2006, 3:26.
34. Sutherland M.S., Sanderson R.J., Gordon K.A., Andreyka J., Cerveny C.G., Yu C., Lewis T.S., Meyer D.L., Zabinski R.F., Doronina S.O., Senter P.D., Law C.L., Wahl A.F. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J. Biol. Chem. 2006, 281:10540.
35. Teeling J.L., French R.R., Cragg M.S., van den Brakel J., Pluyter M., Huang H., Chan C., Parren P.W., Hack C.E., Dechant M., Valerius T., van de Winkel J.G., Glennie M.J. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004, 104:1793.
36. Thie H., Meyer T., Schirrmann T., Hust M., Dubel S. Phage display derived therapeutic antibodies. Curr. Pharm. Biotechnol. 2008, 9:439.
37. Weiner G.J. Monoclonal antibody mechanisms of action in cancer. Immunol. Res. 2007, 39:271.
38. Weiner L.M., Dhodapkar M.V., Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009, 373:1033.
39. Weiner L.M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10:317.
40. Wels W., Beerli R., Hellmann P., Schmidt M., Marte B.M., Kornilova E.S., Hekele A., Mendelsohn J., Groner B., Hynes N.E. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int. J. Cancer 1995, 60:137.
41. Wels W., Harwerth I.M., Mueller M., Groner B., Hynes N.E. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res. 1992, 52:6310.
42. Wu A.M., Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 2005, 23:1137.
43. Younes A., Bartlett N.L., Leonard J.P., Kennedy D.A., Lynch C.M., Sievers E.L., Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 2010, 363:1812.